Quantitative Radionuclide Studies of Bone

Blake, Glen M.; Frost, Michelle L.; Fogelman, Ignac

doi:10.2967/jnumed.109.063263

Cited by 31 publications

(27 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The advent of single photon emission tomography (SPECT) in particular in combination with computed tomography (CT) has further increased the diagnostic accuracy of planar bone scintigraphy and its clinical applications [4,5]. Increasing implementation of PET/CT devices and use of 18 F labeled agents in the last few years has rekindled the interest in using 18 F-NaF.…”

Section: Introductionmentioning

confidence: 98%

“…However, its clinical use was limited at that time mainly due to its high 511 keV energy annihilation photons, the logistic difficulties in delivering a tracer with short half-life of 110 min, as well as due to the less than ideal features of conventional gamma cameras. With the advent of the first technetium-99 m ( 99m Tc) based phosphonates in the late 1970s and the development of the Anger camera, 18 F-NaF was largely replaced by 99m Tc-labeled phosphonates that have optimal characteristics for conventional gamma cameras [2,3].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

18F-NaF PET/CT: EANM procedure guidelines for bone imaging

Beheshti

Mottaghy

Payche

et al. 2015

Eur J Nucl Med Mol Imaging

135

View full text Add to dashboard Cite

The aim of this guideline is to provide minimum standards for the performance and interpretation of (18)F-NaF PET/CT scans. Standard acquisition and interpretation of nuclear imaging modalities will help to provide consistent data acquisition and numeric values between different platforms and institutes and to promote the use of PET/CT modality as an established diagnostic modality in routine clinical practice. This will also improve the value of scientific work and its contribution to evidence-based medicine.

show abstract

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

18F-NaF PET/CT: EANM procedure guidelines for bone imaging

Beheshti

Mottaghy

Payche

et al. 2015

Eur J Nucl Med Mol Imaging

135

View full text Add to dashboard Cite

show abstract

“…Therefore, the local changes in SUVs are affected by the competition for the available tracer across the entire body, including the rest of the skeleton. (33) If the skeletal effects of teriparatide led to the same percentage increase in regional plasma clearance values across the whole skeleton, one would expect the change in spine K i to be partly explained by an increase in SUVs and partly by a decrease in 18 F À plasma concentration, with the latter reflecting the larger proportion of the injected dose being laid down in bone in response to treatment. A 24% increase in K i values in the spine with no change in SUVs suggests that the skeletal effects of teriparatide must differ at different sites, with the small or absent change in SUVs at the spine explained by greater increases in K i at other sites in the skeleton, which take up more of the injected dose, leaving less available for uptake in the spine.…”

Section: Discussionmentioning

confidence: 99%

Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography

Frost

Siddique

Blake

et al. 2010

Journal of Bone and Mineral Research

Self Cite

View full text Add to dashboard Cite

Teriparatide increases skeletal mass, bone turnover markers, and bone strength, but local effects on bone tissue may vary between skeletal sites. We used positron emission tomography (PET) to study 18 F-fluoride plasma clearance (K i ) at the spine and standardized uptake values (SUVs) at the spine, pelvis, total hip, and femoral shaft in 18 postmenopausal women with osteoporosis. Subjects underwent a 1-hour dynamic scan of the lumbar spine and a 10-minute static scan of the pelvis and femurs at baseline and after 6 months of treatment with 20 mg/day teriparatide. Blood samples were taken to derive the arterial input function and lumbar spine K i values evaluated using a three-compartment model. SUVs were calculated for the spine, pelvis, total hip, and femoral shaft. After 6 months treatment with teriparatide, spine K i values increased by 24% (p ¼ .0003), while other model parameters were unchanged except for the fraction of tracer going to bone mineral (k 3 /[k 2 þ k 3 ]), which increased by 23% (p ¼ .0006). In contrast to K i , spine SUVs increased by only 3% (p ¼ .84). The discrepancy between changes in K i and SUVs was explained by a 20% decrease in 18 F À plasma concentration. SUVs increased by 37% at the femoral shaft (p ¼ .0019), 20% at the total hip (p ¼ .032), and 11% at the pelvis (p ¼ .070). Changes in bone turnover markers and BMD were consistent with previous trials. We conclude that the changes in bone formation rate during teriparatide treatment as measured by 18 F À PET differ at different skeletal sites, with larger increases in cortical bone than at trabecular sites. ß

show abstract

“…In clinical practice, bone histomorphometry is substituted with biochemical serum markers of bone metabolism, including alkaline phosphatase, and urinary N-telopeptide and C-telopeptide of collagen cross-links (3). Although such markers display relatively rapid treatmentinduced changes, they are significantly limited by large day-to-day variations and insensitivity to regional changes because they reflect bone metabolism of the entire skeleton (24). Therefore, quantitative imaging of bone metabolism is of considerable interest for specialized clinical indications.…”

Section: Radiotracer Localization To Bonementioning

confidence: 99%

Dynamic Bone Imaging with^99mTc-Labeled Diphosphonates and¹⁸F-NaF: Mechanisms and Applications

2013

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to (1) appreciate the physiologic mechanisms underlying uptake of bone-seeking radiopharmaceuticals used to assess bone perfusion and turnover and note the differences between 18 F-NaF and 99m Tc-labeled diphosphonates; (2) discuss the use of bone scintigraphy for evaluation of bone viability and metabolic bone disorders and appreciate the potential role of quantitative dynamic 18 F-NaF PET for evaluation of response to therapy; and (3) discuss indications for 99m Tc-labeled diphosphonate bone scans and 18 F-NaF PET/CT for oncologic staging and appreciate quantitative methods on static and dynamic bone imaging as imaging biomarkers of treatment response using novel systemic therapies for metastatic castrate-resistant prostate cancer as a model.Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, participants can access this activity through the SNMMI Web site (http:// www.snmmi.org/ce_online) through April 2016.Dynamic bone scanning with 99m Tc-labeled diphosphonates and 18 F-labeled sodium fluoride provides functional information sensitive for subtle changes in bone turnover and perfusion, which assists the clinical management of numerous osseous pathologies. This article reviews the mechanisms of uptake of 99m Tc-labeled diphosphonates and 18 F-sodium fluoride and discusses and compares the performance of these bone-seeking radiotracers for clinical and research applications, using dynamic and multiple-time-point imaging protocols and quantitative techniques.

show abstract

Quantitative Radionuclide Studies of Bone

Cited by 31 publications

References 38 publications

18F-NaF PET/CT: EANM procedure guidelines for bone imaging

18F-NaF PET/CT: EANM procedure guidelines for bone imaging

Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography

Dynamic Bone Imaging with^99mTc-Labeled Diphosphonates and¹⁸F-NaF: Mechanisms and Applications

Contact Info

Product

Resources

About

Quantitative Radionuclide Studies of Bone

Cited by 31 publications

References 38 publications

18F-NaF PET/CT: EANM procedure guidelines for bone imaging

18F-NaF PET/CT: EANM procedure guidelines for bone imaging

Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography

Dynamic Bone Imaging with99mTc-Labeled Diphosphonates and18F-NaF: Mechanisms and Applications

Contact Info

Product

Resources

About

Dynamic Bone Imaging with^99mTc-Labeled Diphosphonates and¹⁸F-NaF: Mechanisms and Applications